Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma
Abstract
The majority of broad-panel tumor genomic profiling has used a gene-centric approach, although much of that data is unused in clinical decision making. We hypothesized that a pathway-centric approach using next-generation sequencing (NGS), combined with conventional clinicopathologic features, may better predict disease-free survival (DFS) in early stage lung adenocarcinoma.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 13, 2019
- Source ID
- 10.1158/1078-0432.ccr-19-1651
Entities
People
- Daniela Molena
- David B Solit
- Fan Yang
- Francisco Sanchez-vega
- Gregory D. Jones
- James Huang
- James M. Isbell
- Jian Zhou
- Kay See Tan
- Marc Ladanyi
- Matthew Bott
- Michael F. Berger
- Natasha Rekhtman
- Nikolaus Schultz
- Prasad S Adusumilli
- Raul Caso
- Smita Sihag
- Valerie W. Rusch
- Walid K. Chatila
- Whitney S. Brandt
- Yan Shi
Organizations
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute
- National Institutes of Health
- Peking University
- United States Department of Defense